Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
Matthew Loper, Abdul Qadar, Sara K Vesely...
https://pubmed.ncbi.nlm.nih.gov/42031503/Actively Recruiting
Led by University of Oklahoma · Updated on 2026-03-05
46
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the combination of two medications, relugolix and enzalutamide, to see how effective and safe this treatment is for patients with high-risk locally advanced prostate cancer. This phase Ib trial aims to improve outcomes by using these drugs as neoadjuvant and adjuvant androgen deprivation therapy alongside standard treatments, such as radiation therapy or prostatectomy. The study also focuses on understanding changes in biomarkers and overall disease progression. Participants will receive relugolix and enzalutamide orally, with a loading dose of relugolix on the first day followed by daily dosing. The treatment includes six months of neoadjuvant therapy before radiation or surgery, followed by 18 months of maintenance adjuvant therapy. The initial safety phase will enroll up to 12 patients, followed by a dose expansion cohort of up to 29 patients. Treatment duration may change if toxicity occurs or if participants choose to withdraw. During the study, participants will be monitored for side effects and treatment responses, including blood tests and assessments of prostate-specific antigen PSA levels. Researchers will track dose limiting toxicities, pathologic complete response rates, and progression-free survival over several years. The total follow-up period after treatment is expected to be around 24 months to evaluate long-term outcomes and safety.
CONDITIONS
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
L
lead onco nurse, RN
K
Kelly Stratton, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Oklahoma
Lead Sponsor
Pfizer
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Relugolix + Enzalutamide (Dose-Escalation and Expansion Protocol) | Guideline-Recommended Neoadjuvant Androgen Deprivation Therapy (GnRH Agonist/Antagonist) |
|---|---|---|
| What it is | A combination of oral Relugolix (120 mg daily, loading dose day 1) and oral Enzalutamide (120–160 mg daily), delivered sequentially as neoadjuvant ADT, concurrent with radiation, and post-radiation maintenance therapy in high-risk locally advanced prostate adenocarcinoma. | Standard neoadjuvant androgen deprivation therapy uses a GnRH agonist or antagonist (e.g., leuprolide, goserelin, degarelix), typically delivered for 6 months before and during radiation or surgery. No novel AR antagonists (such as Enzalutamide) are routinely added in frontline neoadjuvant settings for high-risk locally advanced prostate cancer. |
| Role in trial | Serves as the single investigational regimen undergoing safety lead-in (dose escalation), expansion, and sequential deployment as neoadjuvant, concurrent, and maintenance ADT. | Not a trial control; represents guideline-backed standard ADT used outside the trial for similar patients prior to definitive local therapy. |
| Primary use | Studied for potential to optimize neoadjuvant and maintenance ADT outcomes, pathologic response rates, and progression-free survival for high-risk locally advanced prostate cancer. | Used to reduce androgen-driven tumor growth, facilitate definitive local therapy, and improve disease outcomes. Established purpose in high-risk locally advanced prostate cancer management. |
| How it is given or performed | Both drugs are given orally once daily; Relugolix starts with 360 mg loading dose, then 120 mg daily. Enzalutamide is given at 120–160 mg daily. Dose escalation is first followed by dose expansion, then sequential neoadjuvant, concurrent, and maintenance periods. All administration is outpatient and oral. | Standard neoadjuvant ADT is usually delivered as injection or subcutaneous implant (GnRH agonist/antagonist, e.g., leuprolide, goserelin, degarelix) every 1–3 months, starting 2–6 months before definitive therapy. |
| Evidence status | No published results. Evidence is limited to ongoing clinical investigation; safety, tolerability, and efficacy in neoadjuvant locally advanced high-risk prostate cancer remain to be established. | Established efficacy in improving progression-free survival and local control for high-risk locally advanced prostate cancer; supported by multiple randomized trials and guideline statements. |
| Important limitations | Single-arm study design without a randomized comparator; clinical effect and patient outcomes are unestablished in the neoadjuvant/adjuvant locally advanced population. Possible dose or regimen selection limitations remain as dose escalation and expansion aim to establish optimal tolerability. | Standard ADT does not block androgen receptor signaling beyond GnRH suppression. Addition of novel AR antagonists is not yet routine outside clinical trials. Potential for incomplete androgen axis blockade in high-risk disease remains a consideration. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months (6 months neoadjuvant therapy followed by 18 months adjuvant therapy)
Participants receive neoadjuvant and adjuvant hormonal therapy combining relugolix and enzalutamide alongside local treatment such as radiation therapy or surgery.
Repeated visits approximately every 28 days during treatment cycles
Duration - Approximately 24 months
Participants are monitored for approximately 24 months after completing treatment to assess long-term efficacy and safety.
Periodic visits during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Matthew Loper, Abdul Qadar, Sara K Vesely...
https://pubmed.ncbi.nlm.nih.gov/42031503/University of Oklahoma
Lead Sponsor
Pfizer
Collaborating Sponsor